Edelweiss Aggressive Hybrid Fund
The scheme seeks to generate long term growth of capital and current income through a portfolio investing predominantly in equity and equity related instruments and the balance in debt and money market securities.
Growthvine rating: 3/5 — ranked #15 of 36 in category.
Fund basics
| Category | Hybrid: Aggressive |
|---|
| NAV | ₹66.78 (as of 2026-11-13) |
|---|
| AUM | ₹3,875 Cr |
|---|
| Expense ratio | 1.57% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Bharat Lahoti |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 90 days |
|---|
Performance & risk
| 5-year annualised return | 10.73% |
|---|
| Sharpe ratio | 0.48 |
|---|
| Standard deviation | 11.68% |
|---|
| Max drawdown | −28.61% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 121.1% of NIFTY 50 Hybrid Composite Debt 65:35 Index's upside and 97.4% of its downside.
Market cap allocation
| Large cap | 64.9% |
|---|
| Mid cap | 20.1% |
|---|
| Small cap | 15.1% |
|---|
Concentration
| Top 5 holdings | 16.1% |
|---|
| Top 10 holdings | 25.7% |
|---|
| Total holdings | 96 |
|---|
Top holdings
- EDELWEISS ULTRA SHORT TERM FUND — 5.2%
- Clearing Corporation of India Ltd. — 4.9%
- ICICI Bank Ltd. — 4.4%
- Bharti Airtel Ltd. — 3.4%
- HDFC Bank Ltd. — 3.0%
- Reliance Industries Ltd — 2.7%
- State Bank Of India — 2.6%
- Tech Mahindra Limited — 2.1%
- Sun Pharmaceutical Industries Ltd. — 2.1%
- 8.05% SUN PHARM SR A R 27-10-31 P 270328 — 1.9%
Top sectors
Not disclosed.
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 2.7% | Q2 | #15 of 33 |
| 2025 | 6.0% | Q3 | #18 of 33 |
| 2024 | 20.2% | Q1 (Top) | #8 of 33 |
| 2023 | 25.4% | Q1 (Top) | #6 of 33 |
| 2022 | 5.3% | Q2 | #9 of 30 |